Pharmacologic characterization of fluzoparib, a novel poly(ADP‐ribose) polymerase inhibitor undergoing clinical trials. Issue 3 (19th February 2019)

• Record Type: Journal Article
• Authors: Wang, Lei; Yang, Changyong; Xie, Chengying; Jiang, Jiahua; Gao, Mingzhao; Fu, Li; Li, Yun; Bao, Xubin; Fu, Haoyu; Lou, Liguang
• Is Part Of: Cancer science. Volume 110:Issue 3(2019)
• Page Start: 1064
• Page End: 1075
• Publication Date: 2019-02-19
• Subjects: antitumor activity -- fluzoparib -- pharmacokinetics -- poly(ADP‐ribose) polymerase -- toxicity; Cancer -- Periodicals; Neoplasms -- Periodicals; Research -- Periodicals; Electronic journals; 616.994005
• DOI: 10.1111/cas.13947
• Languages: English
• ISSNs: 1347-9032

Abstract

Abstract : Poly(ADP‐ribose) polymerase (PARP) enzymes play an important role in repairing DNA damage and maintaining genomic stability. Olaparib, the first‐in‐class PARP inhibitor, has shown remarkable clinical benefits in the treatment of BRCA ‐mutated ovarian or breast cancer. However, the undesirable hematological toxicity and pharmacokinetic properties of olaparib limit its clinical application. Here, we report the first preclinical characterization of fluzoparib (code name: SHR‐3162), a novel, potent, and orally available inhibitor of PARP. Fluzoparib potently inhibited PARP1 enzyme activity and induced DNA double‐strand breaks, G2 /M arrest, and apoptosis in homologous recombination repair (HR)‐deficient cells. Fluzoparib preferentially inhibited the proliferation of HR‐deficient cells and sensitized both HR‐deficient and HR‐proficient cells to cytotoxic drugs. Notably, fluzoparib showed good pharmacokinetic properties, favorable toxicity profile, and superior antitumor activity in HR‐deficient xenografts models. Furthermore, fluzoparib in combination with apatinib or with apatinib plus paclitaxel elicited significantly improved antitumor responses without extra toxicity. Based on these findings, studies to evaluate the efficacy and safety of fluzoparib (phase II) and those two combinations (phase I) have been initiated. Taken together, our results implicate fluzoparib as a novel attractive PARP inhibitor. Abstract : Fluzoparib, a novel and potent PARP inhibitor undergoing phase II clinical trials, displays favorable pharmacokinetic properties and superior in vivo antitumor activity compared with olaparib. For the first time, we discover that fluzoparib in combination with apatinib and paclitaxel elicits significantly improved antitumor responses without extra toxicity. Based on this finding, a phase I study has been initiated.